The 87 references in paper B. Lukichev G., A. Karunnaya V., A. Rumyantsev Sh., Б. Лукичёв Г., О. Подгаецкая Ю., А. Карунная В., А. Румянцев Ш. (2014) “Индоксил сульфат при хронической болезни почек // Indoxyl sulphate at chronic kidney disease” / spz:neicon:nefr:y:2014:i:1:p:25-32

1
Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63 (5): 1934-1943
(check this in PDF content)
2
Bergstrom J, Furst P. Uremic toxins. Kidney Int 1978; 8 (Suppl. 1): 9-12
(check this in PDF content)
3
Rutkowski P. Kliniczne i metaboliczne nastêpstwa zatrucia mocznicowego. Przegl Lek 2006; 63 (4): 209-217
(check this in PDF content)
4
Vanholder R, De Smet R, Lameire NH. Redesigning the map of uremic toxins. Contrib Nephrol 2001; 133: 42-70
(check this in PDF content)
5
Chiang CK, Tanaka T, Nangaku M. Dysregulated oxygen metabolism of the kidney by uremic toxins: review. J Ren Nutr 2012; 22(1): 77-80
(check this in PDF content)
6
Синюхин ВН, Стецюк ЕА, Арзуманов СВ. Экспериментальная и клиническая урология 2013; 1: 30-35
(check this in PDF content)
7
Cohen G, Glorieux G, Thornalley P et al. Review on uraemic toxins III. Recommendation for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. NDT 2007; 22: 3381–3390
(check this in PDF content)
8
Сивков АВ, Синюхин ВН, Бебешко ЕВ. Уремический токсин паракрезол у больных с терминальной стадией ХПН. Экспериментальная и клиническая урология 2012; No1: 68-71
(check this in PDF content)
9
Vanholder R, Schepers E, Pletinck A et al. An update on protein-bound uremic retention solutes. J Ren Nutr 2012; 22 (1): 90-94
(check this in PDF content)
10
Wengle B, Hellström K. Volatile phenols in serum of uraemic patients. Clin Sci 1972; 43:493-498
(check this in PDF content)
11
Niwa T. Phenol and p-cresol accomuiated in uremic serum measured by HPLC with fluorescence detection. Clin Chem 1993; 39: 108-111
(check this in PDF content)
12
Niwa T, Ise M, Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994; 14(3):207-212
(check this in PDF content)
13
Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96–104
(check this in PDF content)
14
Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344: 102-107
(check this in PDF content)
15
Kochanek KD, Xu J, Murphy SL, Minino AM, Kung HS. Deaths: preliminary Data for 2009. Nat Vital Stat Rep 2011;4:59
(check this in PDF content)
16
Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ.Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16:489-495
(check this in PDF content)
17
Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология. 2005; 9(3):7–15
(check this in PDF content)
18
Шутов АМ, Серов ВА. Кардиоренальный и ренокардиальный синдромы. Нефрология 2009; 13(4):59-63
(check this in PDF content)
19
Bammens B, Evenepoel P, Verbeke K et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relative with uremic symptoms. Kidney Int 2003; 64: 2238–2243
(check this in PDF content)
20
Bammens B, Evenepoel P, Keuleers H et al. Free serum concentration of the protein-bound retention solute p-cresol predicts mortality in hemodialysis patients. Kidney Int 2006; 69: 1081–1087
(check this in PDF content)
21
Smet R, Kaer J van, Vlem B et al. Toxicity of free pcresol: a prospective and cross-sectional analysis. Clin Chemistry 2003; 49: 470–478
(check this in PDF content)
22
Liabeuf S, Drüeke TB, Massy ZA. Protein-Bound Uremic Toxins: New Insight from Clinical Studies. Toxins 2011; 3: 911-919
(check this in PDF content)
23
Sirich TL, Luo FJ, Plummer NS, Hostetter TH, Meyer TW. Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 2012; 27(4):1574-1579
(check this in PDF content)
24
Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081–1087
(check this in PDF content)
25
Enomoto A, Takeda M, Tojo A et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13: 1711–1720
(check this in PDF content)
26
Cheng-Jui Lin, Chih-Kuang Chuang, Hsuan-Liang Liu et al. The serum levels of P-cresol and Indoxyl sulfate in different hemodialysis vintage. J Clin Medicine and Research 2011; 3(8): 114-119
(check this in PDF content)
27
Meert N, Beerenhout C, Schepers E, Glorieux G, Kooman J,Vanholder R. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009; 22 (3): 352-357
(check this in PDF content)
28
Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R. Behavior of nonprotein- bound and proteinbound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002; 40 (2): 339-347
(check this in PDF content)
29
Martinez A, Recht N, Hostetter T, Meyer T. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430–3437
(check this in PDF content)
30
Smet R, David F, Sandra P, Van Kaer J et al A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin him Acta 1998; 278: 1-21
(check this in PDF content)
31
Loor H, Bammens B, Evenepoel P et al. Gas chromatographic- mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51(8): 1535-1538
(check this in PDF content)
32
Niwa T. Update of uremic toxin research by mass spectrometry. Mass Spectrom 2011; 30(3):510-521
(check this in PDF content)
33
Niwa T, Miyazaki T, Tsukushi S et al. Accumulation of indoxil-beta-D-glucuronide in uremic serum: supression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 1996; 74: 72–78
(check this in PDF content)
34
Lin CJ, Wu CJ, Pan CF et al. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3693–3700
(check this in PDF content)
35
Meijers BK, Bammens B, de Moor et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174–1180
(check this in PDF content)
36
Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997; 62 (Suppl 1) S23-S28
(check this in PDF content)
37
Sanaka T, Sugino N, Teraoka S, Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97–103
(check this in PDF content)
38
Fujii H, Nishijima F, Goto S et al.Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009; 24: 2089–2095
(check this in PDF content)
39
Lin CJ, Chen HH, Pan CF et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011;25(3):191-197
(check this in PDF content)
40
Curtius HC, Mettler M, Ettlinger L. Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 1976; 126: 569–580
(check this in PDF content)
41
Vanholder R, Meert N, Schepers E et al. Review on uraemic solutes II–Variability in reported concentrations: causes and consequences. NDT 2007; 22: 3115–3121
(check this in PDF content)
42
Burchell B, Coughtrie MW. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect 1997; 105 (Suppl. 4): 739–747
(check this in PDF content)
43
Vanholder R, Bammens B, de Loor H et al. The unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 2011; 26(5): 1464–1467
(check this in PDF content)
44
Vanholder R, van Laecke S, Glorieux G. What is new in uremic toxicity? Pediatr Nephrol 2008;23(8):1211–1221
(check this in PDF content)
45
Meijers BK, Evenepoel P. The gut–kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26(3): 759-761
(check this in PDF content)
46
Carvalho JT Jr, Dalboni MA, Watanabe R et al. Effects of spermidine and p-cresol on polymorphonuclear cell apoptosis and function. Artif Organs 2011; 35(2): 27-32
(check this in PDF content)
47
Галишон П, Гертиг А. Эпителиально-мезенхимальная трансформация как биомаркер почечного фиброза: готовы ли мы применить теоретические знания на практике? Нефрология 2013; 17 (4): 9-16
(check this in PDF content)
48
Miyazaki T, Ise M, Hirata M et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl 1997; 63: S211–S214
(check this in PDF content)
49
Adijiang A, Shimizu H, Higuchi Y et al. Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats. J Ren Nutr 2011; 21: 105–109
(check this in PDF content)
50
Namba S, Okuda Y, Morimoto A et al. A serum indoxil sulfate is a useful predictor of chronic kidney disease. Rinsho Byori 2010; 58(5):448-453
(check this in PDF content)
51
Nii-Kono T, Iwasaki Y, Uchida M et al. Indoxil sulfate induces skeletal resistance to parathyreoid hormone in cultured osteoblastic cell. Kidney Int 2007: April,71(8);738-743
(check this in PDF content)
52
Chiang CK, Tanaka T, Inagi R et al. Indoxil sulfate, a representative uremic toxin suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011; 91(11):1564-1571
(check this in PDF content)
53
Shimizu H, Bolati D, Adijiang A et al Indoxil sulfate downregulates renal expression of Klotho troungh production of ROS and activation of nuclear factor-kB. Am J Nephrol 2011:33(4);319324
(check this in PDF content)
54
Kawakami T, Inagi R, Wada T et al. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol 2010;299(3):F568-F576
(check this in PDF content)
55
Shimizu H, Bolati D, Adijiang A et al. Senescence and dysfunction of proximal tubular cells are associated with activated p 53 expression by indoxil sulfate. J Cell Physiol 2010; 299(5): 1110-1117
(check this in PDF content)
56
Oda T, Yung Y, Kim H et al. PAI-1 deficiency attenuates the fibrigenic response to uretral obstruction. Kidney Int 2001; 60: 587–596
(check this in PDF content)
57
Wooin Lee, Richard B. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; V 44: 137-166
(check this in PDF content)
58
Richard B. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; V 44: 137-166
(check this in PDF content)
59
Taki K, Nakamura S, Miglinas M, Enomoto A, Niwa T. Accumulation of indoxyl sulfate in OAT1/3-positive tubular cells in kidneys of patients with chronic renal failure. J Ren Nutr 2006 Jul;16(3):199-203
(check this in PDF content)
60
Hosoya K, Tachikawa M. Role organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin Exper Nephrol 2011; 15(4):478-485
(check this in PDF content)
61
Бердникова НГ. Особенности фармакокинетики лекарственных средств при заболеваниях почек и у больных на гемодиализе. В: Кукес ВГ., ред. Клиническая фармакокинетика: теоретические, прикладные и аналитические аспекты. ГЭОТАР-Медиа, М., 2009; 186-197
(check this in PDF content)
62
Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010; 72: 1 – 11
(check this in PDF content)
63
W u IW, Hsu KH, Lee CC et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011;26(3):938-947
(check this in PDF content)
64
Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6 (5): 30–39
(check this in PDF content)
65
Miyamoto Y, Watanabe H, Otagiri M, Maruyama T. New insight into the redox properties of uremic solute indoxyl sulfate as a pro- and anti-oxidant. Ther Apher Dial 2011;15 (2): 129–131
(check this in PDF content)
66
Motojima M, Nishuima F, Ikoma M et al. Role for ”uremic toxin” in progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461–46
(check this in PDF content)
67
Niwa T, Miyazaki T, Hashimoto N et al. Suppressed serum and urine levels of indoxil sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992; 12: 201–206
(check this in PDF content)
68
Rottenbourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993; 43 (Suppl. 40): S106–S110
(check this in PDF content)
69
Gelasco AK, Raymond JR. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 2006 Jun; 290(6):F1551-8
(check this in PDF content)
70
Motojima M, Hosokawa A, Yamato H et al. Uraemic toxins induced proximal tubular injury via organic anion transporter 1-mediated uptake. Br J Pharmacol 2002; 135: 555–563
(check this in PDF content)
71
Motojima M, Hosokawa A, Yamamoto H et al. Uremic toxins of organic anions upregulate PAI-1 expression by induction of NF –kB and free radicalsin proximal tubular cells. Kidney Int 2003; 63 (6): 1671-1680
(check this in PDF content)
72
Кузьмин ОБ. Механизмы развития и прогрессирования нефропатии у больных сердечной недостаточностью с хроническим кардиоренальным синдромом. Нефрология 2011;15, 2:20-29
(check this in PDF content)
73
Niwa T. Role of indoxil sulfate in the progression of chronic kidneydisease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 2011;15(2);120-124
(check this in PDF content)
74
Barreto F et al. Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clin J. Of the American Society of Nephrology 2009; 4(10):1551-1558
(check this in PDF content)
75
Fuji H, Nakai K, Fukagawa M. Role of oxidative stress and indoxil sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial 2011;15(20): 125-128
(check this in PDF content)
76
Dou L, Bertrand E, Cerini C et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442–451
(check this in PDF content)
77
Dou L, Jourde-Chiche N, Faure V et al. The uremic solute indoxil sulfate induces oxidative stress in endothelial cells. J Thromb Heamost 2007; 5(6);1302-1308
(check this in PDF content)
78
Miyamoto Y, Watanabe H, Otagiri M, Maruyama T. New Insinght into the redox properties of uremic solute indoxil sulfate as a pro and anti-oxidant. Ther Apher Dial 2011;15(2);129-131
(check this in PDF content)
79
Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa A R et al. Does indoxil sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31(14):1771-1779
(check this in PDF content)
80
Schepers E, Meert N, Glorieux G et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596
(check this in PDF content)
81
Meijers BK, Claes K, Bammens B et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182–1189
(check this in PDF content)
82
Taki K, Tsuruta Y, Niwa T. Indoxil Sulfate and atherosclerotic Risk Factors in Hemodialysis Patients. Nephrology 2007; 27(1): 30 – 35
(check this in PDF content)
83
Owada S, Goto S, Bannai K, Hayashi H, Nishijima F, Niwa T. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 2008;28(3):446-54
(check this in PDF content)
84
Adijiag A, Goto S, Uramoto S, Nishijima F, Niwa T/ Indoxil sulfate promotes aortic calcification with expression of osteoblastspecific proteins in hypertensive rats. Nephrol Dial Transplant 2008; 23(6);1892-1901
(check this in PDF content)
85
Yamamoto H, Tsuruoka S, Ioka T et al. Indoxil sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006;69:1780-1785
(check this in PDF content)
86
Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, Yamato H, Kurokawa K, Fukagawa M. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71: 738–743
(check this in PDF content)
87
Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006; 21: 2768–2774 Авторы заявляют об отсутствии конфликта
(check this in PDF content)